ATE469176T1 - Modifizierter anti-tnf antikörper - Google Patents

Modifizierter anti-tnf antikörper

Info

Publication number
ATE469176T1
ATE469176T1 AT02787636T AT02787636T ATE469176T1 AT E469176 T1 ATE469176 T1 AT E469176T1 AT 02787636 T AT02787636 T AT 02787636T AT 02787636 T AT02787636 T AT 02787636T AT E469176 T1 ATE469176 T1 AT E469176T1
Authority
AT
Austria
Prior art keywords
chain variable
light chain
variable region
modified
heavy
Prior art date
Application number
AT02787636T
Other languages
English (en)
Inventor
Koen Hellendoorn
Matthew Baker
Francis J Carr
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Application granted granted Critical
Publication of ATE469176T1 publication Critical patent/ATE469176T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT02787636T 2001-11-12 2002-11-11 Modifizierter anti-tnf antikörper ATE469176T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01126858 2001-11-12
PCT/EP2002/012566 WO2003042247A2 (en) 2001-11-12 2002-11-11 Modified anti-tnf alpha antibody

Publications (1)

Publication Number Publication Date
ATE469176T1 true ATE469176T1 (de) 2010-06-15

Family

ID=8179220

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02787636T ATE469176T1 (de) 2001-11-12 2002-11-11 Modifizierter anti-tnf antikörper

Country Status (17)

Country Link
US (2) US7524502B2 (de)
EP (1) EP1448602B1 (de)
JP (1) JP4304073B2 (de)
KR (1) KR20050044405A (de)
CN (1) CN1585778A (de)
AT (1) ATE469176T1 (de)
AU (1) AU2002351957B2 (de)
BR (1) BR0213565A (de)
CA (1) CA2466592A1 (de)
DE (1) DE60236536D1 (de)
ES (1) ES2346517T3 (de)
HU (1) HUP0402333A3 (de)
MX (1) MXPA04004417A (de)
PL (1) PL369739A1 (de)
RU (1) RU2004117915A (de)
WO (1) WO2003042247A2 (de)
ZA (1) ZA200404626B (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040009166A1 (en) * 1997-04-30 2004-01-15 Filpula David R. Single chain antigen-binding polypeptides for polymer conjugation
JP2002505574A (ja) * 1997-04-30 2002-02-19 エンゾン，インコーポレイテッド ポリアルキレンオキシド修飾された単鎖ポリペプチド
US7101978B2 (en) 2003-01-08 2006-09-05 Applied Molecular Evolution TNF-α binding molecules
US8147832B2 (en) * 2003-08-14 2012-04-03 Merck Patent Gmbh CD20-binding polypeptide compositions and methods
JP4804357B2 (ja) 2003-11-01 2011-11-02 メルク パテント ゲーエムベーハー 改変抗ｃｄ５２抗体
US7435799B2 (en) 2004-01-08 2008-10-14 Applied Molecular Evolution TNF-α binding molecules
GB0425713D0 (en) 2004-11-23 2004-12-22 Baker Matthew Immunogencity testing and antibody selection methods
JP2008528668A (ja) 2005-02-03 2008-07-31 アンチトープ リミテッド ヒト抗体及びタンパク質
EP1869192B1 (de) * 2005-03-18 2016-01-20 MedImmune, LLC Rahmenmischung von antikörpern
CA2608332A1 (en) * 2005-05-12 2006-11-23 Attenuon, Llc Treatment of inflammatory bowel disease (ibd) with anti-angiogenic compounds
RU2464276C2 (ru) 2005-05-18 2012-10-20 Аблинкс Н.В. Улучшенные нанотела против фактора некроза опухоли-альфа
ES2535426T3 (es) * 2005-08-04 2015-05-11 Janssen Biotech, Inc. Anticuerpos anti-TNFα y métodos de uso
CA3161849A1 (en) * 2007-01-30 2008-08-07 Epivax, Inc. Regulatory t cell epitopes, compositions and uses thereof
WO2009014835A2 (en) 2007-06-21 2009-01-29 Angelica Therapeutics, Inc. Modified toxins
EP2268297A4 (de) 2008-02-29 2011-11-16 Angelica Therapeutics Inc Modifizierte toxine
AU2010298036B2 (en) 2009-09-25 2015-05-21 Xoma Technology Ltd. Screening methods
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
MX2012004877A (es) 2009-10-26 2012-05-23 Prometheus Lab Inc Analisis para la deteccion de farmacos anti-tnf y autoanticuerpos.
AU2011307886C1 (en) * 2010-09-30 2015-07-09 Chengdu Kanghong Biotechnologies Co., Ltd. Anti TNF alpha humanized antibody and fragment antigen binding (Fab) and use thereof
KR102344129B1 (ko) 2010-10-08 2021-12-30 시티 오브 호프 메디토프를 위한 단일클론 항체 프레임워크 결합 계면, 메디토프 전달 시스템 및 이의 사용 방법
US8962804B2 (en) 2010-10-08 2015-02-24 City Of Hope Meditopes and meditope-binding antibodies and uses thereof
SG189391A1 (en) 2010-10-18 2013-05-31 Nestec Sa Methods for determining anti-drug antibody isotypes
CN102675460B (zh) * 2011-02-28 2015-08-19 珠海市丽珠单抗生物技术有限公司 抗肿瘤坏死因子α的人源化抗体
US8658171B2 (en) 2011-02-28 2014-02-25 Livzon Mabpharm Inc. Humanized anti-TNFα antibodies
AU2012278802B2 (en) 2011-07-06 2015-11-26 Société des Produits Nestlé S.A. Assays for detecting neutralizing autoantibodies to biologic therapy with TNF alpha
US9428553B2 (en) 2012-02-10 2016-08-30 City Of Hope Meditopes and meditope-binding antibodies and uses thereof
CA2902905A1 (en) 2013-03-15 2014-09-25 Claude Geoffrey Davis Modified toxins
CN105377297B (zh) * 2013-05-28 2019-09-17 Dcb-美国有限责任公司 用于蛋白质药物失活的抗体锁扣
RU2556816C1 (ru) * 2014-03-12 2015-07-20 Открытое акционерное общество "Фармацевтический импорт, экспорт" (ОАО "Фармимэкс") Штамм клеток яичников китайского хомячка - продуцент рекомбинантного антитела против фактора некроза опухоли альфа человека
JP2018500553A (ja) 2014-12-05 2018-01-11 ネステク ソシエテ アノニム 患者試料における生物製剤の検出のための間接的均一移動度シフトアッセイ
CN105820246A (zh) 2015-01-07 2016-08-03 上海张江生物技术有限公司 一种新型重组抗TNFα嵌合单克隆抗体制备方法及用途
US10947305B2 (en) 2015-03-20 2021-03-16 Full Spectrum Genetics, Inc. Anti-TNFα binding compounds and uses thereof
SG10202001787QA (en) 2016-06-02 2020-04-29 Abbvie Inc Glucocorticoid receptor agonist and immunoconjugates thereof
EP3602314A4 (de) 2017-03-30 2021-03-03 Blonder Tongue Laboratories, Inc. Unternehmensinhaltsgateway
CA3082356A1 (en) 2017-12-01 2019-06-06 Abbvie Inc. Glucocorticoid receptor agonist and immunoconjugates thereof
US20220389092A1 (en) * 2019-04-05 2022-12-08 The Regents Of The University Of California Methods and compositions involving chimeric binding polypeptides
CN111909267B (zh) * 2019-05-07 2022-03-25 北京天成新脉生物技术有限公司 低免疫原性抗TNF-α人源化单克隆抗体TCX063及其应用
GB202004916D0 (en) * 2020-04-02 2020-05-20 Univ Oxford Innovation Ltd Antibodies
EP4232063A4 (de) * 2020-10-23 2025-01-01 HAN, Hq Bifunktionelle antagonisten des tumornekrosefaktors-alpha und transformierenden wachstumsfaktor-beta und deren verwendungen
CN121548746A (zh) * 2023-06-08 2026-02-17 辛特里亚公司 用于检测针对抗TNFα抗体的中和抗体(NAb)的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US6277969B1 (en) * 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US5919452A (en) * 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
EP1097945B1 (de) * 1991-03-18 2007-07-04 New York University Monoklonale und chimäre Antikörper spezifisch für menschlichen Tumornekrosefaktor
US5519000A (en) * 1994-04-01 1996-05-21 Centecor, Inc. Tumor necrosis factor inhibitors
CU22615A1 (es) * 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
DE69833755T2 (de) * 1997-05-21 2006-12-28 Biovation Ltd. Verfahren zur herstellung von nicht-immunogenen proteinen
US6835550B1 (en) * 1998-04-15 2004-12-28 Genencor International, Inc. Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins
AU776910B2 (en) * 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
EP1230269A2 (de) * 1999-11-03 2002-08-14 Maxygen, Inc. Erzeugung von antikörperdiversität
UA81743C2 (uk) * 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
WO2002069232A2 (en) * 2001-02-19 2002-09-06 Merck Patent Gmbh Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity

Also Published As

Publication number Publication date
JP4304073B2 (ja) 2009-07-29
RU2004117915A (ru) 2005-05-10
EP1448602A2 (de) 2004-08-25
WO2003042247A2 (en) 2003-05-22
EP1448602B1 (de) 2010-05-26
US7754853B2 (en) 2010-07-13
JP2005510216A (ja) 2005-04-21
US20040260069A1 (en) 2004-12-23
WO2003042247A3 (en) 2004-03-11
US7524502B2 (en) 2009-04-28
AU2002351957B2 (en) 2009-09-03
US20060018903A1 (en) 2006-01-26
PL369739A1 (en) 2005-05-02
CA2466592A1 (en) 2003-05-22
KR20050044405A (ko) 2005-05-12
MXPA04004417A (es) 2004-08-11
DE60236536D1 (de) 2010-07-08
ES2346517T3 (es) 2010-10-18
ZA200404626B (en) 2005-10-26
BR0213565A (pt) 2004-10-26
HUP0402333A2 (hu) 2005-02-28
HUP0402333A3 (en) 2007-05-02
CN1585778A (zh) 2005-02-23

Similar Documents

Publication Publication Date Title
ATE469176T1 (de) Modifizierter anti-tnf antikörper
HRP20090517T1 (hr) Protutijela na interleukin-10
EA200700136A1 (ru) Анти-cd154-антитела
HUS1600019I1 (hu) Polipeptideket tartalmazó készítmények
EA200600313A1 (ru) Связывающие конструкции и способы их применения
EA200600126A1 (ru) Антитела против tnf, композиции, способы и применения
IL200373A (en) A monoclonal antibody that binds to 3erbb and a pharmacological preparation that includes the same to inhibit 3erbb signaling in humans
UA89017C2 (uk) ЛЮДСЬКЕ АНТИТІЛО, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ЛЮДСЬКИМ TNFSF13b
CR20130155A (es) PROTEÍNAS DE LA UNIÓN A IL-12/P40 (Divisional 9599)
MXPA05007853A (es) Antagonistas de il-1 beta humana.
SI2481753T1 (en) Anti-IL-17 antibodies
CY1118709T1 (el) Αντιγονικα πεπτιδια του παραγοντα διεγερσης αποικιων των κοκκινοκυτταρων (gm-csf) και αντισωματα για ton gm-csf
CY1110877T1 (el) Αλλαγη των συγγενειων συνδεσης me fcrn ή των ημιζωων ορου αντισωματων με μεταλλαξιγενεση
EA201001528A1 (ru) Антитела к склеростину и способы их применения
TW200716745A (en) Anti-TNF antibodies, compositions, methods and uses
AR068508A1 (es) Anticuerpo capaz de enlazar linfopoyetina estromal timica
EA200870538A1 (ru) Лиофилизированные композиции анти-egfr антител
ATE541590T1 (de) Modifizierte antikörper-fragmente
EA200870208A1 (ru) Конструкт однодоменного антитела
WO2007117577A3 (en) High affinity human antibodies to human il-18 receptor
IS8016A (is) Prótín sem bindast viðtaka NOGO
IL302575A (en) IL-2R BETA GAMMA c BINDING COMPOUNDS AND USES THEREOF
JOP20220348A1 (ar) ميوتينات il-10 وبروتينات دمجها
RU2380377C2 (ru) Nogo-A-СВЯЗЫВАЮЩИЕ МОЛЕКУЛЫ И ИХ ФАРМАЦЕВТИЧЕСКОЕ ПРИМЕНЕНИЕ
WO2024148232A3 (en) Anti-il18 binding protein antibodies and methods of use thereof

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties